José Baselga was inaugurated as president of the American Association for Cancer Research for 2015-2016, during the association’s annual meeting in Philadelphia.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
